Loading organizations...
Inbiomotion builds precision medicine solutions for oncology, centered on its flagship MAF Test®. This biomarker-based diagnostic tool enhances patient selection for adjuvant bisphosphonate treatment in early breast cancer. By identifying individuals at risk of bone metastasis through specific single-gene biomarkers, the test enables more targeted therapeutic strategies.
Founded in 2011, Inbiomotion emerged as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. Professor Dr. Roger Gomis established the company based on his pioneering discovery of the MAF gene as a crucial predictor of bone metastasis, translating this scientific insight into a clinical diagnostic.
Oncologists leverage the MAF Test® to inform personalized treatment decisions for breast cancer patients. Inbiomotion’s vision is to improve patient outcomes and quality of life by providing accurate, actionable diagnostics, ensuring individuals receive optimal, tailored therapies guided by their unique biological profiles.
Inbiomotion has raised $4.0M across 2 funding rounds.
Inbiomotion has raised $4.0M in total across 2 funding rounds.
Inbiomotion has raised $4.0M across 2 funding rounds. Most recently, it raised $2.0M Series B in March 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2016 | $2M Series B | — | Caixa Capital Risc, EQT Life Sciences, Faber, Kurma Partners, Roche Venture Fund, Sanofi Ventures, Ysios Capital | Announced |
| Jun 1, 2012 | $2M Series A | — | Caixa Capital Risc, EQT Life Sciences, Faber, Kurma Partners, Roche Venture Fund, Sanofi Ventures, Ysios Capital | Announced |
Inbiomotion has raised $4.0M in total across 2 funding rounds.
Inbiomotion's investors include Caixa Capital, EQT Life Sciences, Faber, Kurma Partners, Roche Venture Fund, Sanofi Ventures, Ysios Capital.
Inbiomotion is a Barcelona-based biotechnology company specializing in precision medicine for breast cancer, developing the MAF Test®, a single-gene biomarker diagnostic kit that detects MAF gene amplification to predict bone metastasis risk and guide adjuvant bisphosphonate treatment in early-stage (I-III) patients.[1][2][3][7] It serves oncologists, pathologists, and breast cancer patients by identifying those who benefit from bisphosphonates—improving survival and reducing relapse—while sparing others unnecessary or harmful treatment, addressing the uncertainty where 1 in 4 early-stage patients may develop metastasis, often to bone.[1][3][5][7] Growth momentum includes clinical validation from landmark trials (NSABP-B34, AZURE), partnerships for distribution in Spain/Portugal (Palex Medical, 2022), Italy (SPA Farma), UK/Ireland (Source BioScience), and Sub-Saharan Africa, plus over 200 patents and backing from investors like Ysios Capital and Caixa Capital Risc.[2][3][4][7]
Founded in 2010-2011 as a spin-off from the Barcelona Institute for Biomedical Research (IRB Barcelona) and ICREA, Inbiomotion emerged from Prof. Roger Gomis's discovery of the MAF gene as a biomarker for bone metastasis in breast cancer.[1][3][4][7] Gomis, a co-founder and IRB researcher, identified MAF amplification's role in stratifying patients, leading to the company's focus on companion diagnostics for bone-modifying agents like bisphosphonates.[2][3] Early traction came from accessing major trials (e.g., NSABP-B34 in 2018 via NCI/NRG Oncology) and publications in *The Lancet Oncology* and *Journal of the National Cancer Institute*, confirming the test's utility in selecting patients for clodronate treatment.[2][4] Pivotal leadership additions, like Ralf van den Berg as COO (2022) and Dr. Jon Askaa as non-executive Director, supported commercialization.[2]
Inbiomotion rides the precision oncology wave, targeting breast cancer's high unmet need—2.2 million global cases yearly, leading female cancer deaths—by enabling biomarker-driven therapy amid rising demand for companion diagnostics post-genomic sequencing advances.[3][6][7] Timing aligns with bisphosphonate trial data maturation (e.g., AZURE/NSABP-B34) and regulatory pushes for personalized medicine, as overtreatment burdens healthcare amid 25% metastasis risk in early cases.[2][7] Market forces like expanding IVD access in Europe/Italy and investor biotech funding favor it, influencing the ecosystem by setting a model for single-gene tests in adjuvant settings, potentially standardizing MAF testing and improving survival rates while cutting costs.[3][4][7]
Inbiomotion is poised for broader adoption as MAF Test® gains routine use in guidelines, fueled by ongoing validations and partnerships expanding to new markets. Trends like AI-enhanced diagnostics and global precision med mandates will amplify its edge, evolving it from niche biomarker firm to key player in breast cancer personalization—potentially halving relapse risks for targeted patients. Watch for US/FDA traction and combo therapies, tying back to its core mission: transforming breast cancer from life-threatening to manageable through actionable biology.[2][3][7]
